Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-Acting, Self-Administered HIV Therapy with the CCR5 Antibody PRO 140 ("NIAID Study")

X
Trial Profile

Long-Acting, Self-Administered HIV Therapy with the CCR5 Antibody PRO 140 ("NIAID Study")

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leronlimab (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms NIAID
  • Most Recent Events

    • 30 Mar 2022 Status changed from planning to suspended, according to a CytoDyn media release
    • 30 Mar 2022 According to a CytoDyn media release, the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on Leronlimab HIV program.The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved.
    • 29 Apr 2013 After a 3-year delay, an agreement has been reached with Ajinomoto Althea, a fill and finish plan has been put in place, and enrolment is expected to start in the fourth quarter of 2013, according to a CytoDyn media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top